First Interchangeable Biosimilar Launched In US
Viatris And Biocon Introduce Semglee And Unbranded Insulin Glargine Biosimilars
Viatris and Biocon have introduced their interchangeable Semglee insulin glargine biosimilar in the US, along with an unbranded interchangeable version, marking the first ever launch of an interchangeable biosimilar. The non-interchangeable version is expected to be phased out rapidly.